{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Brolucizumab 6 mg",
        "type": {
          "id": "8e7614cd-35e2-45d2-92a1-4a7aec6ae897",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "10579cbb-c114-4a90-81d2-3bfd2457add4",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Anti-VEGF single-chain antibody fragment (scFv) for proliferative diabetic retinopathy",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Panretinal photocoagulation (PRP)",
        "type": {
          "id": "01afdbf7-d221-4fae-9ee9-857a25fd3b7d",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "ff23679d-987d-42a2-b386-cbc2e625a3a7",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Standard of care laser treatment for proliferative diabetic retinopathy",
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Topical ocular medications",
        "type": {
          "id": "e3fe4734-3884-4e2e-9d5a-c44d7f184a2a",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "cadd2f64-edc9-4093-95c2-10a30fccf28c",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted during the study, including corticosteroids",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Corticosteroids (non-ocular)",
        "type": {
          "id": "f18637e3-3b79-4c8c-974d-b8131de0ad62",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "ad7674fe-762f-408f-ab3f-229bc0974add",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted via intra-nasal, inhaled, intra-articular, or non-extensive dermal routes",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Anti-VEGF therapy (other than study drug)",
        "type": {
          "id": "fc3813b5-1baa-4ee9-961f-8a709e75c310",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "6a1b17f1-c308-404f-b5fd-9428f5ae29b4",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited in the study eye and systemically",
        "administrationIds": [
          "admin_5"
        ]
      },
      {
        "id": "int_6",
        "name": "Fluocinolone acetonide intravitreal implant",
        "type": {
          "id": "79538af4-e818-43f9-9b4a-e8ed9906eaf3",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "cd20b9f3-3cc9-43d5-a469-c10462b2e6fc",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited prior to baseline and during study"
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Brolucizumab",
        "administrableDoseForm": {
          "id": "2478c363-9c01-4cdd-b8e8-f20e5e63d9e3",
          "code": "C42986",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Solution",
          "standardCode": {
            "id": "9b686845-b5c0-4d8a-aba2-c252dccd1ab6",
            "code": "C42986",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Solution",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "0871a25b-20af-468d-8396-82adbee96ce6",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "6 mg/0.05 mL",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Novartis"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Brolucizumab Loading Phase",
        "instanceType": "Administration",
        "dose": "6 mg",
        "doseFrequency": "Every 6 weeks (3 doses)",
        "route": {
          "code": "Other",
          "codeSystem": "USDM",
          "decode": "Other"
        },
        "duration": "Baseline, Week 6, and Week 12"
      },
      {
        "id": "admin_2",
        "name": "Brolucizumab Maintenance Phase",
        "instanceType": "Administration",
        "dose": "6 mg",
        "doseFrequency": "Every 12 weeks",
        "route": {
          "code": "Other",
          "codeSystem": "USDM",
          "decode": "Other"
        },
        "duration": "Week 18 through Week 90"
      },
      {
        "id": "admin_3",
        "name": "Brolucizumab Extension Phase",
        "instanceType": "Administration",
        "dose": "6 mg",
        "doseFrequency": "Extended by 6-week increments up to every 24 weeks",
        "route": {
          "code": "Other",
          "codeSystem": "USDM",
          "decode": "Other"
        },
        "duration": "From Week 48 onwards based on disease stability"
      },
      {
        "id": "admin_4",
        "name": "PRP Initial Treatment",
        "instanceType": "Administration",
        "dose": "1500-5000 burns",
        "doseFrequency": "1 to 4 sessions",
        "route": {
          "code": "Topical",
          "codeSystem": "USDM",
          "decode": "Topical"
        },
        "duration": "Up to Week 12"
      },
      {
        "id": "admin_5",
        "name": "PRP Maintenance (PRN)",
        "instanceType": "Administration",
        "dose": "As needed",
        "doseFrequency": "As needed (Pro re nata)",
        "route": {
          "code": "Topical",
          "codeSystem": "USDM",
          "decode": "Topical"
        },
        "duration": "From Week 18 to Week 90"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Brolucizumab",
        "instanceType": "Substance",
        "description": "Single-chain antibody fragment (scFv) inhibitor of vascular endothelial growth factor A (VEGF-A)"
      }
    ],
    "medicalDevices": [
      {
        "id": "dev_1",
        "name": "Conventional lasers or automated pattern delivery systems",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      }
    ],
    "summary": {
      "interventionCount": 6,
      "productCount": 1,
      "deviceCount": 1
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Brolucizumab 6 mg",
        "role": "Investigational Product",
        "description": "Anti-VEGF single-chain antibody fragment (scFv) for proliferative diabetic retinopathy"
      },
      {
        "name": "Panretinal photocoagulation (PRP)",
        "role": "Comparator",
        "description": "Standard of care laser treatment for proliferative diabetic retinopathy"
      },
      {
        "name": "Topical ocular medications",
        "role": "Concomitant Medication",
        "description": "Permitted during the study, including corticosteroids"
      },
      {
        "name": "Corticosteroids (non-ocular)",
        "role": "Concomitant Medication",
        "description": "Permitted via intra-nasal, inhaled, intra-articular, or non-extensive dermal routes"
      },
      {
        "name": "Anti-VEGF therapy (other than study drug)",
        "role": "Concomitant Medication",
        "description": "Prohibited in the study eye and systemically"
      },
      {
        "name": "Fluocinolone acetonide intravitreal implant",
        "role": "Concomitant Medication",
        "description": "Prohibited prior to baseline and during study"
      }
    ],
    "products": [
      {
        "name": "Brolucizumab",
        "doseForm": "Solution for injection",
        "strength": "6 mg/0.05 mL",
        "manufacturer": "Novartis"
      }
    ],
    "substances": [
      {
        "name": "Brolucizumab",
        "description": "Single-chain antibody fragment (scFv) inhibitor of vascular endothelial growth factor A (VEGF-A)"
      }
    ],
    "administrations": [
      {
        "name": "Brolucizumab Loading Phase",
        "dose": "6 mg",
        "frequency": "Every 6 weeks (3 doses)",
        "route": "Intravitreal",
        "duration": "Baseline, Week 6, and Week 12"
      },
      {
        "name": "Brolucizumab Maintenance Phase",
        "dose": "6 mg",
        "frequency": "Every 12 weeks",
        "route": "Intravitreal",
        "duration": "Week 18 through Week 90"
      },
      {
        "name": "Brolucizumab Extension Phase",
        "dose": "6 mg",
        "frequency": "Extended by 6-week increments up to every 24 weeks",
        "route": "Intravitreal",
        "duration": "From Week 48 onwards based on disease stability"
      },
      {
        "name": "PRP Initial Treatment",
        "dose": "1500-5000 burns",
        "frequency": "1 to 4 sessions",
        "route": "Topical (Laser)",
        "duration": "Up to Week 12"
      },
      {
        "name": "PRP Maintenance (PRN)",
        "dose": "As needed",
        "frequency": "As needed (Pro re nata)",
        "route": "Topical (Laser)",
        "duration": "From Week 18 to Week 90"
      }
    ],
    "devices": [
      {
        "name": "Conventional lasers or automated pattern delivery systems",
        "manufacturer": "Not specified",
        "purpose": "Administration of panretinal photocoagulation"
      }
    ]
  }
}